

Critical Path Institute's Predictive Safety Testing Consortium Announces First-Ever Qualification Decision by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).

For the first time, new biomarker tests to detect drug-induced kidney injury have been accepted by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).